Role of GLP1-RA in Optimizing Weight Loss Post-Bariatric Surgery: A Systematic Review and Meta-Analysis

Obes Surg. 2024 Oct;34(10):3888-3896. doi: 10.1007/s11695-024-07486-w. Epub 2024 Aug 31.

Abstract

Bariatric surgery is a widely used intervention for significant weight loss, yet some patients face challenges with insufficient weight loss or weight regain post-surgery. To address this issue, adjunctive treatments like glucagon-like peptide-1 receptor agonists (GLP1-RAs) are being explored for their potential to enhance weight loss outcomes. This meta-analysis was conducted to evaluate the effectiveness of GLP1-RAs in improving weight loss after bariatric surgery compared to a placebo. By systematically reviewing and analyzing data from three randomized controlled trials (RCTs) involving 130 patients, we found that GLP1-RA therapy, particularly liraglutide (1.8-3 mg), significantly reduced mean BMI and body weight percentage at six months. Future studies should explore newer GLP1-RAs with weekly dosing and include longer follow-up periods to assess the durability of these outcomes.

Keywords: Bariatric surgery; GLP1-RAs; Metabolic surgery; Obesity; Weight regain.

Publication types

  • Systematic Review
  • Meta-Analysis
  • Review

MeSH terms

  • Bariatric Surgery*
  • Body Mass Index
  • Female
  • Glucagon-Like Peptide-1 Receptor Agonists* / pharmacology
  • Glucagon-Like Peptide-1 Receptor Agonists* / therapeutic use
  • Humans
  • Liraglutide* / pharmacology
  • Liraglutide* / therapeutic use
  • Male
  • Obesity, Morbid* / drug therapy
  • Obesity, Morbid* / surgery
  • Randomized Controlled Trials as Topic
  • Treatment Outcome
  • Weight Loss* / drug effects

Substances

  • Liraglutide
  • Glucagon-Like Peptide-1 Receptor Agonists